Skin-brightening cosmetic peptide (Oligopeptide-68)
A synthetic peptide used in skincare products to reduce dark spots and uneven skin tone; a cosmetic ingredient, not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Cosmetic peptide — MITF-pathway signal peptide
Evidence tier: In vitro / assay evidence
Status: Cosmetic ingredient; no drug approval identified in attached sources
Best-supported effect: Reduction of melanogenesis markers in cellular and reconstructed-skin assay systems, with proposed MITF-pathway suppression
Main caveat: Efficacy data is primarily manufacturer-sponsored; independent peer-reviewed clinical replication is limited and no rigorous head-to-head trials against established depigmenting agents are identified in available literature
What this is
Oligopeptide-68 is a synthetic ten-amino-acid peptide (Arg-Asp-Gly-Gln-Ile-Leu-Ser-Thr-Trp-Tyr) developed as a topical cosmetic brightening ingredient. It is marketed as the active component in β-WHITE™, a branded ingredient developed by Lucas Meyer Cosmetics (now part of IFF). Unlike tyrosinase inhibitors such as hydroquinone, kojic acid, or decapeptide-12, Oligopeptide-68 is proposed to act upstream at the transcriptional level by suppressing MITF (microphthalmia-associated transcription factor), which in turn reduces downstream expression of tyrosinase, TRP-1, and TRP-2. It is used in topical serums, creams, and spot treatments at typical formulated concentrations of 1.0–2.5% of the β-WHITE™ ingredient.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | Weak | Manufacturer-sponsored clinical studies report pigmentation improvement endpoints over 8–12 week topical application; independent peer-reviewed replication is limited and no controlled RCTs are identified in available literature |
| Animal | Weak | In vitro melanocyte and reconstructed-skin-model studies support the transcriptional-suppression mechanism; dedicated animal studies are described as sparse in available literature |
| In vitro | Moderate | Cellular melanogenesis assays report reduced pigmentation markers consistent with MITF-pathway suppression; assay data forms the strongest evidence base in attached sources |
| Computational | None identified | No computational or docking data attached |
| Mechanism | Plausible | MITF is a well-characterized master regulator of the melanocyte differentiation program; transcriptional modulation is a biologically sensible strategy; however, the specific receptor-level entry point of the peptide is not resolved in the public literature |
The majority of the efficacy and tolerability evidence described in the available literature originates from manufacturer-sponsored studies and marketing materials for β-WHITE™. Independent peer-reviewed clinical replication and head-to-head comparisons against established depigmenting agents are explicitly described as limited or absent in available literature.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Reduces melanogenesis markers in cellular assay systems | Supported (in vitro) | In vitro | Medium — manufacturer-associated assay data; independent replication not confirmed in source |
| Reduces visible hyperpigmentation and skin brightening (topical cosmetic use) | Weak | Human — manufacturer-sponsored clinical testing only | Low — no independent peer-reviewed RCTs identified in source |
| Acts upstream of tyrosinase by suppressing MITF transcriptional activity | Partially supported (in vitro) | In vitro | Medium — biologically plausible; specific receptor-level mechanism not resolved in public literature |
| Superior or equivalent to hydroquinone for hyperpigmentation | Not established | None | Low — no rigorous head-to-head trials identified in source |
| Safe for topical cosmetic use | Weak | Human — manufacturer-sponsored tolerability data | Low — limited to manufacturer-reported data; independent safety study data not extracted |
Assay conditions
This section reports concentrations or conditions used in assays. It does not establish animal or human exposure.
| Context | System | Assay condition | Timepoint | Endpoint | Limitation |
|---|---|---|---|---|---|
| Cellular melanogenesis assay | Melanocyte cell cultures and reconstructed skin models | β-WHITE™ formulation; exact peptide concentration and assay protocol not individually extracted in source | Not individually extracted | MITF expression, tyrosinase expression, melanin content markers | In vitro only; does not establish in vivo or clinical equivalence |
| Manufacturer-sponsored clinical testing | Human subjects (topical application) | β-WHITE™ formulation at 1.0–2.5% typical product concentration | 8–12 weeks per source description | Pigmentation improvement endpoints (instrument-measured) | Manufacturer-sponsored; not independently replicated per source; assay protocol and population details not individually extracted |
Assay limitations
- All clinical and cellular efficacy data described in available literature originate from or are associated with the manufacturer (Lucas Meyer Cosmetics / IFF); independent peer-reviewed replication is explicitly described as limited.
- The specific molecular entry point through which Oligopeptide-68 engages the MITF pathway is not resolved in the public literature; manufacturer materials describe the transcriptional effect but do not definitively establish whether the peptide acts at a surface receptor, intracellularly, or through a secondary signaling intermediate.
- Dermal bioavailability is an unresolved challenge: stratum-corneum penetration is a general limitation for decapeptide topicals, and vehicle and carrier systems materially affect delivery to the melanocyte compartment.
- Head-to-head comparisons against established depigmenting agents (hydroquinone, tretinoin, azelaic acid, kojic acid) are described as scarce in available literature.
- Long-term safety of sustained MITF suppression in melanocytes is not established in attached sources.
- No human safety data extending beyond manufacturer-sponsored tolerability reports are identified.
Regulatory status
No approved therapeutic or drug status identified in attached sources. Oligopeptide-68 is a cosmetic ingredient (INCI name: Oligopeptide-68), not an approved drug. The β-WHITE™ branded ingredient is sold for use in topical cosmetic formulations.
| Region / body | Status | Notes |
|---|---|---|
| US | Cosmetic ingredient | No FDA drug approval identified; regulated as cosmetic ingredient only |
| EU | Cosmetic ingredient | per available sources cosmetic use; regulatory detail not individually extracted |
| WADA | Not checked | Anti-doping relevance not applicable to topical cosmetic ingredient use; not checked in this card |
Mechanism
Oligopeptide-68 is proposed to act as a signal peptide that suppresses MITF (microphthalmia-associated transcription factor) expression or activity in melanocytes. MITF is the central transcriptional regulator of the melanocyte differentiation program; it drives expression of the core melanogenic enzymes tyrosinase, TRP-1 (tyrosinase-related protein 1), and TRP-2 (dopachrome tautomerase), as well as structural proteins involved in melanosome organization. By downregulating MITF, the peptide is proposed to reduce enzyme production downstream, producing a net decrease in eumelanin synthesis over time.
This mechanism distinguishes Oligopeptide-68 from direct enzymatic inhibitors such as hydroquinone, kojic acid, and arbutin, which block tyrosinase at the catalytic level. The transcriptional approach is biologically plausible — MITF's role is well-characterized — and peptide-mediated transcription factor modulation is an established strategy in cosmetic actives.
The critical gap in public literature is the receptor-level mechanism: how the peptide reaches or influences MITF activity. Whether it acts at a surface receptor, intracellularly, or through a secondary signaling intermediate is not definitively resolved in published independent work. The target confidence is therefore inferred from assay observations, not directly validated from a defined receptor-binding study.
Chemistry
| Field | Value |
|---|---|
| Sequence | Arg-Asp-Gly-Gln-Ile-Leu-Ser-Thr-Trp-Tyr |
| One-letter code | RDGQILSTWY |
| Length | 10 amino acids |
| Topology | Linear |
| CAS | 1206525-47-4 |
| Modification | None described; unmodified decapeptide |
| Formulation context | Typically 1.0–2.5% of β-WHITE™ ingredient in finished topical cosmetic products |
| Sequence confidence | Needs review — sequence is as provided in available literature; no cross-source verification performed in this card |
Open questions
- Receptor-level mechanism: What specific molecular target or pathway does Oligopeptide-68 engage to suppress MITF? Is there a surface receptor interaction, or does the peptide act intracellularly? This gap limits mechanistic confidence.
- Independent clinical replication: No independent peer-reviewed RCTs or controlled trials are identified in available literature. Replication by non-manufacturer groups is a key evidence gap.
- Head-to-head comparisons: How does Oligopeptide-68 compare in efficacy and durability to established depigmenting agents (hydroquinone, tretinoin, azelaic acid, kojic acid, niacinamide) in rigorous head-to-head trials?
- Dermal bioavailability: What dermal penetration does Oligopeptide-68 achieve in clinically relevant vehicles, and does it reach the melanocyte compartment in active concentrations?
- Long-term MITF suppression safety: MITF regulates melanocyte survival and differentiation beyond pigmentation alone. Long-term safety of sustained suppression in melanocytes is not characterized in attached sources.
- Effect durability after discontinuation: Whether the brightening effect is maintained, reversed, or requires continuous application is not established in available literature.
- Additive vs redundant effects in combination formulations: Oligopeptide-68 is commonly used alongside niacinamide, tranexamic acid, vitamin C, and azelaic acid; whether combinations produce additive effects or redundant mechanistic overlap is not resolved in available literature.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does Oligopeptide-68 work only on the skin's pigment cells, not on surrounding cells, simply because those are the only cells that express the MITF gene it suppresses?
If YKFLR naturally avoids non-pigment skin cells, it would be inherently safer than broad skin-bleaching agents like hydroquinone, which affect all cell types and carry long-term risks. This would support its use in sensitive populations and at higher concentrations than current formulations allow.
▸3-letter notation
▸citationbibtex
@peptide{pep10954,
sequence = {YKFLR},
target = {},
author = {peptidemodel},
year = {2026},
status = {designed}
}